Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03473301 : A Study of UCB and MSCs in Children With CP: ACCeNT-CP
PhasePhase 1/Phase 2
AgesMin: 24 Months Max: 60 Months
Eligibility
Inclusion Criteria:

1. Age =24 months and =60 months adjusted age at the time of enrollment.

2. Diagnosis: Unilateral or bilateral hypertonic cerebral palsy secondary to in utero or
perinatal stroke/hemorrhage, hypoxic ischemic encephalopathy (including, but not
limited to, birth asphyxia), and/or periventricular leukomalacia.

3. Performance status: Gross Motor Function Classification Score levels I - IV

4. Review of brain imaging (obtained as standard of care prior to study entry) does not
suggest a genetic condition or brain malformation.

5. Legal authorized representative consent.

Exclusion Criteria:

1. Available qualified autologous cord blood unit.

2. Hypotonic or ataxic cerebral palsy without spasticity.

3. Autism and autistic spectrum disorders.

4. Hypsarrhythmia.

5. Legally blind

6. Intractable seizures causing epileptic encephalopathy.

7. Evidence of a progressive neurologic disease.

8. Has an active, uncontrolled systemic infection or documentation of HIV+ status.

9. Known genetic disease or phenotypic evidence of a genetic disease on physical exam.

10. Concurrent genetic or acquired disease or comorbidity(ies) that could require a future
allogeneic stem cell transplant.

11. Requires ventilatory support, including home ventilator, CPAP, BiPAP, or supplemental
oxygen.

12. Impaired renal or liver function as determined by serum creatinine >1.5mg/dL and/or
total bilirubin >1.3mg/dL except in patients with known Gilbert's disease.

13. Possible immunosuppression, defined as WBC <3,000 cells/mL or absolute lymphocyte
count (ALC) <1500 with abnormal T-cell subsets.

14. Patient's medical condition does not permit safe travel.

15. Previously received any form of cellular therapy.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT03473301      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740